Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034296784> ?p ?o ?g. }
- W3034296784 abstract "There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack of consensus on the best outcome measures for controlled trials. This systematic review aimed to evaluate the efficacy of GLP-1 RAs in the management of NAFLD, the degree of heterogeneity in trial design and the robustness of conclusions drawn from these clinical trials. We searched publication databases and clinical trial registries through 2 November 2019 for clinical trials with NAFLD. We evaluated improvements in histological findings, noninvasive markers of hepatic steatosis, inflammation, and fibrosis, insulin resistance and anthropometric measures. Our final analysis included 24 clinical trials, comprising 6313 participants with a mean duration of 37 weeks. Four clinical trials, including RCT (n = 1), single-arm studies (n = 2) and case series studies (n = 1), used biopsy-confirmed liver histological change as their end-points. The remaining studies (n = 20) used surrogate end-points. GLP-1 RAs were effective for the improvement in hepatic inflammation, hepatic steatosis and fibrosis. More importantly, GLP-1 RAs showed promise in improving the histological features of NASH. In addition, 8 ongoing trials were identified. In this systematic review of published and ongoing clinical trials of the efficacy of GLP-1RAs for NAFLD, we found that GLP-1 RAs are effective for hepatic steatosis and inflammation, with the potential to reverse fibrosis. Further prospective studies of sufficient duration using histological end-points are needed to fully assess the efficacy of GLP-1 RAs in the management of NAFLD." @default.
- W3034296784 created "2020-06-19" @default.
- W3034296784 creator A5006531603 @default.
- W3034296784 creator A5051025753 @default.
- W3034296784 creator A5079674453 @default.
- W3034296784 creator A5083447643 @default.
- W3034296784 creator A5089960678 @default.
- W3034296784 creator A5090129293 @default.
- W3034296784 date "2020-06-11" @default.
- W3034296784 modified "2023-10-14" @default.
- W3034296784 title "Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review" @default.
- W3034296784 cites W1539916041 @default.
- W3034296784 cites W1570155932 @default.
- W3034296784 cites W1609508996 @default.
- W3034296784 cites W1917816261 @default.
- W3034296784 cites W1942040918 @default.
- W3034296784 cites W1943482912 @default.
- W3034296784 cites W1947853286 @default.
- W3034296784 cites W1969295126 @default.
- W3034296784 cites W1969489686 @default.
- W3034296784 cites W1973939264 @default.
- W3034296784 cites W1975388439 @default.
- W3034296784 cites W1975489439 @default.
- W3034296784 cites W1983417944 @default.
- W3034296784 cites W1983581861 @default.
- W3034296784 cites W1987727907 @default.
- W3034296784 cites W1995000970 @default.
- W3034296784 cites W1997425045 @default.
- W3034296784 cites W2004554777 @default.
- W3034296784 cites W2006766845 @default.
- W3034296784 cites W2011499650 @default.
- W3034296784 cites W2015450018 @default.
- W3034296784 cites W2021388182 @default.
- W3034296784 cites W2022271042 @default.
- W3034296784 cites W2029772633 @default.
- W3034296784 cites W2031887619 @default.
- W3034296784 cites W2033283875 @default.
- W3034296784 cites W2038028662 @default.
- W3034296784 cites W2041468536 @default.
- W3034296784 cites W2042706232 @default.
- W3034296784 cites W2054285552 @default.
- W3034296784 cites W2062618014 @default.
- W3034296784 cites W2070710390 @default.
- W3034296784 cites W2086719465 @default.
- W3034296784 cites W2087484038 @default.
- W3034296784 cites W2091106363 @default.
- W3034296784 cites W2098923148 @default.
- W3034296784 cites W2103135709 @default.
- W3034296784 cites W2103299980 @default.
- W3034296784 cites W2109371472 @default.
- W3034296784 cites W2112515812 @default.
- W3034296784 cites W2113064802 @default.
- W3034296784 cites W2113983413 @default.
- W3034296784 cites W2120056458 @default.
- W3034296784 cites W2129316761 @default.
- W3034296784 cites W2134833483 @default.
- W3034296784 cites W2136795008 @default.
- W3034296784 cites W2146837981 @default.
- W3034296784 cites W2159123653 @default.
- W3034296784 cites W2164375919 @default.
- W3034296784 cites W2204688218 @default.
- W3034296784 cites W2215535790 @default.
- W3034296784 cites W2237544788 @default.
- W3034296784 cites W2252839338 @default.
- W3034296784 cites W2255641665 @default.
- W3034296784 cites W2299992793 @default.
- W3034296784 cites W2323606868 @default.
- W3034296784 cites W2336168218 @default.
- W3034296784 cites W2337473245 @default.
- W3034296784 cites W2409172672 @default.
- W3034296784 cites W2433376106 @default.
- W3034296784 cites W2462595066 @default.
- W3034296784 cites W2470709274 @default.
- W3034296784 cites W2520975418 @default.
- W3034296784 cites W2529114944 @default.
- W3034296784 cites W2530347223 @default.
- W3034296784 cites W2531626219 @default.
- W3034296784 cites W2555995017 @default.
- W3034296784 cites W2560450505 @default.
- W3034296784 cites W2568210207 @default.
- W3034296784 cites W2588681363 @default.
- W3034296784 cites W2589426226 @default.
- W3034296784 cites W2598765141 @default.
- W3034296784 cites W2615637571 @default.
- W3034296784 cites W2616178818 @default.
- W3034296784 cites W2734724639 @default.
- W3034296784 cites W2751367256 @default.
- W3034296784 cites W2770634512 @default.
- W3034296784 cites W2774655822 @default.
- W3034296784 cites W2774672890 @default.
- W3034296784 cites W2791708447 @default.
- W3034296784 cites W2794639926 @default.
- W3034296784 cites W2801929531 @default.
- W3034296784 cites W2805588616 @default.
- W3034296784 cites W2810643620 @default.
- W3034296784 cites W2901944682 @default.
- W3034296784 cites W2902244224 @default.
- W3034296784 cites W2905282109 @default.
- W3034296784 cites W2909812323 @default.
- W3034296784 cites W2914961474 @default.